Results 171 to 180 of about 274,555 (304)

Correction to: Design of an international multicentre RCT on group schema therapy for borderline personality disorder. [PDF]

BMC Psychiatry, 2022
Wetzelaer P, Farrell J, Evers SMAA, Jacob GA, Lee CW, Brand O, van Breukelen G, Fassbinder E, Fretwell H, Harper RP, Lavender A, Lockwood G, Malogiannis IA, Schweiger U, Startup H, Stevenson T, Zarbock G, Arntz A.   +17 more
europepmc   +1 more source

Reconfigurable Magnetic Soft Microrobot for Acoustically Triggered Targeted Bacterial Sterilization

Advanced Functional Materials, EarlyView.
Reconfigurable magnetic soft microrobots integrate in situ‐grown piezoelectric zinc oxide nanorods that produce reactive oxygen species upon acoustic excitation. Combining magnetically guided transport with thermally induced planar reconfiguration, the microrobots achieve targeted delivery and enhanced bacterial sterilization through efficient on ...
Quan Gao, Fan Li, Jiajie Gao, Elric Zhang, Yingdong Su, Ni Qin, Hao Ye, Josep Puigmartí, Giuseppe Cantarella, Simone Schuerle, Jiang Wu, Bradley J. Nelson, Salvador Pané   +12 more
wiley   +1 more source

Integrating Positive Schemas in Schema Therapy for Cluster C Personality Disorders in Older Adults: A Multiple Baseline Study. [PDF]

Clin Psychol Psychother
van Donzel L, Ouwens MA, van Alphen SPJ, Bouwmeester S, Bachrach N, Videler AC.   +5 more
europepmc   +1 more source

Schema therapy for violent PD offenders: a randomized clinical trial. [PDF]

Psychol Med, 2023
Bernstein DP, Keulen-de Vos M, Clercx M, de Vogel V, Kersten GCM, Lancel M, Jonkers PP, Bogaerts S, Slaats M, Broers NJ, Deenen TAM, Arntz A.   +11 more
europepmc   +1 more source

Bimetallic Nanoreactor Activates cGAS‐STING Pathway via mtDNA Release for Cancer Metalloimmunotherapy

Advanced Functional Materials, EarlyView.
A bimetallic Mn–Ca nanoreactor (MCC) is developed as a non‐nucleotide STING nanoagonist for cancer metalloimmunotherapy. MCC induces Ca2+ overload and hydroxyl radical generation, resulting in mitochondrial damage and mtDNA release. The released mtDNA cooperates with Mn2+ to robustly activate cGAS–STING signaling.
Xin Wang Mo, Nguyen Thi Nguyen, LiLi Guo, Ngoc Man Phan, Hyunsu Shin, Tae‐il Kim, Yu Seok Youn, Jaeyun Kim   +7 more
wiley   +1 more source

Correction: Design of an RCT on cost-effectiveness of group schema therapy versus individual schema therapy for patients with cluster-C personality disorder: the QUEST-CLC study protocol. [PDF]

BMC Psychiatry
Groot IZ, Venhuizen ASM, Bachrach N, Walhout S, de Moor B, Nikkels K, Dalmeijer S, Maarschalkerweerd M, van Aalderen JR, de Lange H, Wichers R, Hollander AP, Evers SMAA, Grasman RPPP, Arntz A.   +14 more
europepmc   +1 more source

Correction: Optimizing psychotherapy dosage for comorbid depression and personality disorders (PsyDos): a pragmatic randomized factorial trial using schema therapy and short-term psychodynamic psychotherapy. [PDF]

BMC Psychiatry, 2023
Kool M, Van HL, Bartak A, de Maat SCM, Arntz A, van den Eshof JW, Peen J, Blankers M, Bosmans JE, Dekker JJM.   +9 more
europepmc   +1 more source

Generating Cell Surface Nucleated Hydrogels with an Artificial Membrane‐Binding Transglutaminase

Advanced Functional Materials, EarlyView.
Cell‐based therapies require advanced strategies to enhance cell delivery and bioactivity. Cell membrane engineering offers an avenue to impart new functions to delivered cells to boost their viability and function. Here, an artificial membrane‐binding transglutaminase is generated and biophysically characterized.
Rosalia Cuahtecontzi Delint, Tao Li, Kapil D. Patel, Will H. Zhang, Ben M. Carter, Graham J. Day, Adam W. Perriman   +6 more
wiley   +1 more source

Schema therapy in partially sighted individuals with a focus on social isolation and self-esteem: an interventional study. [PDF]

BMC Psychiatry
Abbasi A, Farokhzadian J, Torkaman M, Miri S.   +3 more
europepmc   +1 more source

Individual psychotherapy for cluster-C personality disorders: protocol of a pragmatic RCT comparing short-term psychodynamic supportive psychotherapy, affect phobia therapy and schema therapy (I-FORCE). [PDF]

Trials, 2023
Daniëls M, Van HL, van den Heuvel B, Dekker JJM, Peen J, Bosmans J, Arntz A, Huibers MJH.   +7 more
europepmc   +1 more source